Jackson Wealth Management LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 11.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,499 shares of the healthcare product maker’s stock after purchasing an additional 3,064 shares during the quarter. Jackson Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,690,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ABT. Sanders Morris Harris LLC increased its position in Abbott Laboratories by 0.3% during the second quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after acquiring an additional 16 shares during the last quarter. St. Louis Trust Co increased its position in Abbott Laboratories by 0.4% during the second quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock valued at $238,000 after acquiring an additional 20 shares during the last quarter. Lakeview Capital Partners LLC increased its position in Abbott Laboratories by 0.6% during the second quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock valued at $277,000 after acquiring an additional 33 shares during the last quarter. Johanson Financial Advisors Inc. increased its position in Abbott Laboratories by 0.5% during the second quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after acquiring an additional 37 shares during the last quarter. Finally, Cobblestone Capital Advisors LLC NY increased its position in Abbott Laboratories by 0.3% during the second quarter. Cobblestone Capital Advisors LLC NY now owns 16,511 shares of the healthcare product maker’s stock valued at $803,000 after acquiring an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 71.21% of the company’s stock.

A number of analysts recently commented on the company. Leerink Swann reiterated a “market perform” rating on shares of Abbott Laboratories in a research report on Friday. Barclays reissued a “buy” rating and set a $66.00 price target on shares of Abbott Laboratories in a report on Monday, January 8th. Royal Bank of Canada reissued a “buy” rating and set a $65.00 price target on shares of Abbott Laboratories in a report on Tuesday, January 9th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Tuesday, January 2nd. Finally, Evercore ISI started coverage on Abbott Laboratories in a report on Wednesday, January 3rd. They set an “outperform” rating and a $64.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $60.24.

Shares of Abbott Laboratories (ABT) opened at $59.31 on Monday. The stock has a market capitalization of $103,235.05, a PE ratio of 46.70, a price-to-earnings-growth ratio of 1.89 and a beta of 1.06. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a fifty-two week low of $39.25 and a fifty-two week high of $59.68.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a $0.28 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.89%. Abbott Laboratories’s dividend payout ratio is 88.19%.

In other news, Chairman Miles D. White sold 276,886 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total value of $15,065,367.26. Following the completion of the transaction, the chairman now owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Brian J. Blaser sold 23,866 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $55.55, for a total value of $1,325,756.30. Following the completion of the transaction, the insider now directly owns 146,387 shares of the company’s stock, valued at approximately $8,131,797.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 404,569 shares of company stock valued at $22,103,095. Corporate insiders own 0.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Abbott Laboratories (ABT) Stake Lifted by Jackson Wealth Management LLC” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/abbott-laboratories-abt-stake-lifted-by-jackson-wealth-management-llc/1817776.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.